Associated Papers
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S1
Mutational profiling of Chinese patients with thyroid cancer.
Du Y et al.
Frontiers in Endocrinology, 2023
37465126 (PubMed )
Supplement: Table_2.xlsx › Supplementary_Table_2
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A et al.
Jto Clinical and Research Reports, 2021
34590037 (PubMed )
Supplement: mmc3.xlsx › LOGIK_VariantMetrics-UserFilter
Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma.
Jiang H et al.
Frontiers in Oncology, 2021
35186718 (PubMed )
Supplement: Table_1.xlsx › Supplementary_Table_2
Exome sequencing identifies somatic mutations in novel driver genes in non-small cell lung cancer.
Zhang M et al.
Aging, 2020
32629428 (PubMed )
Supplement: aging-12-103500-s002..xlsx › Sheet1
The molecular landscape of ETMR at diagnosis and relapse.
Lambo S et al.
Nature, 2019
31802000 (PubMed )
Supplement: NIHMS1541318-supplement-Supplementary_Table_6.xlsx › SNVs_Targeted_Sequencing
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
Rajasekaran R et al.
Applied Biochemistry and Biotechnology, 2010
Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.
Choi JE et al.
Bmc Cancer, 2007
Select a paper to view details